These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25015848)

  • 1. Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU.
    Bruyère R; Quenot JP; Prin S; Dalle F; Vigneron C; Aho S; Leon C; Charles PE
    BMC Infect Dis; 2014 Jul; 14():385. PubMed ID: 25015848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.
    Nolla-Salas J; Sitges-Serra A; León-Gil C; Martínez-González J; León-Regidor MA; Ibáñez-Lucía P; Torres-Rodríguez JM
    Intensive Care Med; 1997 Jan; 23(1):23-30. PubMed ID: 9037636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
    Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
    Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
    Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
    Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.
    Playford EG; Lipman J; Jones M; Lau AF; Kabir M; Chen SC; Marriott DJ; Seppelt I; Gottlieb T; Cheung W; Iredell JR; McBryde ES; Sorrell TC
    Clin Infect Dis; 2016 Dec; 63(11):1463-1469. PubMed ID: 27601224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.
    León C; Ruiz-Santana S; Saavedra P; Galván B; Blanco A; Castro C; Balasini C; Utande-Vázquez A; González de Molina FJ; Blasco-Navalproto MA; López MJ; Charles PE; Martín E; Hernández-Viera MA;
    Crit Care Med; 2009 May; 37(5):1624-33. PubMed ID: 19325481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.
    Martínez-Jiménez MC; Muñoz P; Valerio M; Vena A; Guinea J; Bouza E
    J Antimicrob Chemother; 2015 Nov; 70(11):3107-15. PubMed ID: 26311840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of initial empirical antifungal agents on the outcome of critically ill patients with invasive candidiasis: analysis of the China-SCAN study.
    Cui N; Wang H; Qiu H; Li R; Liu D
    Int J Antimicrob Agents; 2017 Jul; 50(1):74-80. PubMed ID: 28499959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study.
    Bailly S; Leroy O; Azoulay E; Montravers P; Constantin JM; Dupont H; Guillemot D; Lortholary O; Mira JP; Perrigault PF; Gangneux JP; Timsit JF;
    J Infect; 2017 Apr; 74(4):408-417. PubMed ID: 28104387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-d-glucan.
    Nucci M; Nouér SA; Esteves P; Guimarães T; Breda G; de Miranda BG; Queiroz-Telles F; Colombo AL
    J Antimicrob Chemother; 2016 Sep; 71(9):2628-33. PubMed ID: 27287231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit.
    Pagès A; Iriart X; Molinier L; Georges B; Berry A; Massip P; Juillard-Condat B
    Value Health; 2017 Dec; 20(10):1319-1328. PubMed ID: 29241891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units.
    Montravers P; Perrigault PF; Timsit JF; Mira JP; Lortholary O; Leroy O; Gangneux JP; Guillemot D; Bensoussan C; Bailly S; Azoulay E; Constantin JM; Dupont H;
    Clin Microbiol Infect; 2017 Feb; 23(2):117.e1-117.e8. PubMed ID: 27746395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
    Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodriguez A;
    Rev Iberoam Micol; 2014; 31(3):157-75. PubMed ID: 25113990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empiric antifungal and outcome in ICU patients.
    Trifi A; Abdellatif S; Daly F; Nasri R; Touil Y; Ben Lakhal S
    Tunis Med; 2019 Apr; 97(4):579-587. PubMed ID: 31729709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida prophylaxis and therapy in the ICU.
    Echeverria PM; Kett DH; Azoulay E
    Semin Respir Crit Care Med; 2011 Apr; 32(2):159-73. PubMed ID: 21506052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].
    Almirante B; Garnacho-Montero J; Maseda E; Candel FJ; Grau S; Guinea J; Moreno I; Muñoz P; Ruiz-Santana S
    Rev Esp Quimioter; 2017 Oct; 30(5):355-367. PubMed ID: 28945064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
    van der Geest PJ; Rijnders BJ; Vonk AG; Groeneveld AB
    Mycoses; 2016 Mar; 59(3):179-85. PubMed ID: 26707572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy.
    Chastain DB; White BP; Tu PJ; Chan S; Jackson BT; Kubbs KA; Bandali A; McDougal S; Henao-Martínez AF; Cluck DB
    Ann Pharmacother; 2024 Mar; 58(3):305-321. PubMed ID: 37272474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.